Anyone can join the movement by choosing to talk about their experiences with diabetes.

Founded in 1940, our objective is to avoid and cure diabetes and to improve the lives of most people suffering from diabetes. WHEN: November 2, 2009 WHY: With nearly 24 million kids and adults afflicted with the disease in the U.S. And an additional 57 million at risk for type 2 diabetes, diabetes has reached epidemic proportions. If current developments continue, one out of three children shall encounter a future with diabetes. HOW: To allow your viewers/listeners/readers find out about American Diabetes Month and the Quit Diabetes movement.It offers us additional confidence as we move into the next Phase 2a research and we believe it represents a key de-risking event for growing our pipeline of RNAi therapeutics predicated on the DPC platform, stated Christopher Anzalone, Ph.D., President and CEO. The Phase 1 trial was designed to characterize the protection profile of ARC-520 across a variety of doses and assess pharmacokinetics. It really is a single-center, randomized, double-blind, placebo-controlled, solitary dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers.